Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE2
17 participants
INTERVENTIONAL
2021-03-01
2023-06-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Diuretic Use in Hemodialysis Patients With Residual Renal Function
NCT05915286
Aldosterone and Vascular Disease in Diabetes Mellitus
NCT00214825
Aldosterone in Diabetic Nephropathy
NCT00870402
Protocolized Diuretic Strategy in Cardiorenal Failure
NCT01921829
Maximizing the Benefit of Renin-Angiotensin Blocking Drugs in Diabetic Renal Disease.
NCT00240019
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
OTHER
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Metolazone then placebo
Metolazone will be taken orally during the first week, followed by washout of 1-2 weeks, then placebo will be taken the following week.
Metolazone
Participants receive a single dose of metolazone.
Placebo
Participants receive a single dose of placebo to match metolazone.
Placebo then Metolazone
Placebo will be taken orally during the first week, followed by washout of 1-2 weeks, then metolazone will be taken the following week.
Metolazone
Participants receive a single dose of metolazone.
Placebo
Participants receive a single dose of placebo to match metolazone.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Metolazone
Participants receive a single dose of metolazone.
Placebo
Participants receive a single dose of placebo to match metolazone.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* stable dialysis patients who produce urine and able to provide consent
Exclusion Criteria
* recent hospitalization or other event resulting in instability of food intake
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Stanford University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Tammy Lisa Sirich
Assistant Professor of Medicine
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Stanford University
Palo Alto, California, United States
VA Palo Alto Health Care System
Palo Alto, California, United States
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol
Document Type: Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
56566
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.